[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:bard1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"BARD1 Gene",12,8,[8,16,23,30,36,42,48,54,60,67,73,80],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05687110","Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes",[12],"Phase 1","RECRUITING","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.808389Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",[20],"Phase 2","2026-08-26T02:18:38.077159Z","2026-05-05T02:35:31.766251Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05659381","Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer",[27],"Phase 3","2026-08-26T02:17:14.343713Z","2026-05-05T02:43:27.677486Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT05941520","Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer",[20],"2026-08-26T02:17:39.048487Z","2026-07-19T19:36:05.126907Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06195306","Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction",[20],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:26.724920Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07076147","Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer",[],"2026-08-26T02:19:06.150683Z","2026-05-13T02:55:06.650047Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07038785","Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs",[],"2026-08-26T02:18:38.865010Z","2026-05-13T02:55:06.608906Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT04038502","Carboplatin or Olaparib for BRcA Deficient Prostate Cancer",[20],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:29.505079Z",{"nct_id":61,"title":62,"phases":63,"status":64,"updated_at":65,"content_modified":66},"NCT07723651","[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)",[20],"NOT_YET_RECRUITING","2026-08-26T02:19:11.399072Z","2026-07-24T01:27:14.924205Z",{"nct_id":68,"title":69,"phases":70,"status":64,"updated_at":71,"content_modified":72},"NCT07690852","Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care",[],"2026-08-26T02:16:24.970704Z","2026-07-19T19:36:05.153122Z",{"nct_id":74,"title":75,"phases":76,"status":77,"updated_at":78,"content_modified":79},"NCT05498272","Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:05:27.322885Z","2026-05-05T02:43:27.674415Z",{"nct_id":81,"title":82,"phases":83,"status":77,"updated_at":84,"content_modified":85},"NCT04550494","Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",[20],"2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.385344Z"]